Companies ›Consumer Non Cyclicals ›SKIN

SKIN — Nasdaq Personal Products

SkinHealth Systems Inc.

$0,62

Open in Charts → Attach watcher ⌖

— —

USD

Set alert

LatestSkinHealth Systems thesis revised as price action triggers monitor alert

Last 30 days

1D5D1M3M6MYTD1Y5YMax

Live price chart loads from the market-data widget.

Mcap

82,1M USD

P/E

—

EV / Rev

-1,3x

Div yield

—

Op margin

-6,9 %

ROE

-17,2 %

Net margin

-3,2 %

Debt / equity

—

Beta

—

52w range

—

Volume

Day range

—

Prev close

$0,91

Open

—

Next earnings

2026-10-28

Ex-dividend

—

TR 1Y

—

About

SkinHealth Systems Inc. operates in the Medical Equipment & Supplies industry, generating revenue through the sale of advanced skincare devices and proprietary consumables, anchored by the Hydrafacial treatment platform.

Business. SkinHealth Systems Inc. (Nasdaq: SKIN) is a healthcare company engaged in the medical devices industry, specifically within the medical equipment and supplies sector. The firm operates on a product-sale revenue model. As segment and geographic breakdowns are not provided, the company is described at the industry level. It is primarily listed on the Nasdaq stock exchange.

Classification99 %

SectorConsumer Staples

Industry groupPersonal Products

Generated · model-assisted

Sell-side consensus

HOLD9 analysts

1 buy6 hold2 sell

Avg 12m price target1,34

Analyst recommendations

9 analysts · consensus Hold

Buy1

Hold6

Sell2

12-month price target

1,34

Consensus of sell-side coverage.

Upcoming events

EarningsQ3 2026 earnings (expected)2026-10-28 · estimated

See all catalysts →

At a glance

Score

—

not yet scored

Valuation

—

valuation pending

Analysts→

Hold

9 analysts · indicative

Ownership→

FMR LLC

largest disclosed fund holder

Profitability→

-17,2 %

return on equity

Quality

—

not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

MARKETSSkinHealth Systems thesis revised as price action triggers monitor alert2026-07-16

Sector rotation

Sector1D1Mvs mkt

Materials+2,3 %+6,6 %+1,7 %

Communication Services+2,2 %−5,5 %+1,7 %

Energy+0,6 %+3,3 %+0,0 %

Health Care+0,6 %−0,8 %+0,0 %

Consumer Discretionary+0,4 %+7,7 %−0,2 %

Information Technology+0,3 %+7,8 %−0,3 %

Financials−0,3 %−2,8 %−0,9 %

Consumer Staples · THIS SECTOR−0,4 %+2,5 %−1,0 %

Real Estate−0,7 %+10,9 %−1,3 %

Industrials−1,9 %−3,1 %−2,5 %

Utilities−1,9 %+28,2 %−2,5 %

Developing storylines

No tracked sagas currently linked to SKIN. Browse all sagas →

Analysis

AI analysis

Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

Opportunity

— missing data

Upcoming catalysts

Scheduled public events. Informational only — not investment advice.

Company
EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
Macro
Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
Macro & political
ElectionSE Swedish Election2026-09-14 · SE
ElectionUS U.S. Midterms2026-11-03 · US
ElectionFR French Legislative2027-06-01 · FR

Pre-earnings brief

Briefing · model-assisted

SkinHealth Systems Inc. (SKIN) saw three new institutional investors add positions as of March 31, 2026, marking a notable shift in holder activity. The additions include an investor holding 2,241,596 shares valued at approximately $2.0 million, another with 290,550 shares worth roughly $0.26 million, and a third holding 947 shares valued at less than $1,000. These changes were detected on June 20, 2026, and represent the most material recent development in the company’s ownership structure. The entry of these new holders brings the total number of top holders to 22, reflecting a broadening base of institutional interest. While the absolute share counts vary significantly among the new investors, the presence of a multi-million-dollar position suggests growing attention from larger funds. This expansion in holder count may indicate increased visibility or strategic positioning by investors ahead of upcoming earnings or operational updates. Despite the new holder activity, the company’s market share remained effectively unchanged, dipping slightly from 0.01186% to 0.01183%. This minimal fluctuation suggests that the new investments are not yet translating into broader market dominance or significant competitive shifts. The stability in market share underscores that SKIN’s position in its sector remains niche, with limited immediate impact from the recent holder additions. The company continues to operate with a lean leadership structure, maintaining only one officer, and lacks analyst coverage or index membership. With no material changes reported in its core operational metrics or strategic direction, the recent holder activity stands out as the primary catalyst for investor attention. As SKIN navigates this period of evolving ownership, the significance of these new positions will likely depend on future disclosures and performance trends.

Signals & dispatch

peak dispatch · 2026-07-16

Composite-score breakdown

Synthesis

Business

SkinHealth Systems Inc. (Nasdaq: SKIN) is a healthcare company engaged in the medical devices industry, specifically within the medical equipment and supplies sector. The firm operates on a product-sale revenue model. As segment and geographic breakdowns are not provided, the company is described at the industry level. It is primarily listed on the Nasdaq stock exchange.

Classification99 %

SectorConsumer Staples

Industry groupPersonal Products

AI synthesis

GENERATED

SkinHealth Systems maintains a debt-free capital structure with a debt-to-equity ratio of 0.0 and a current ratio of 1.79, indicating adequate short-term liquidity coverage. The balance sheet holds $523.0 million in cash and equivalents against total liabilities of $418.0 million, providing a substantial buffer despite negative operating cash flow of $5.6 million in Q1 2026. The company’s market capitalization stands at $123.9 million, trading at a negative EV/Revenue multiple of -1.33, reflecting its current unprofitability.

Profitability remains negative, with a net loss of $6.6 million in Q1 2026, resulting in a return on equity of -17.2% and return on assets of -2.0%. Gross profit was $44.4 million on revenue of $64.9 million, yielding a gross margin of approximately 68.5%, which supports the high-margin consumables model. However, operating income was negative at -$1.8 million, driven by significant selling, general, and administrative expenses that outpaced gross profit generation.

Revenue is derived from two primary segments: Delivery Systems and Consumables, with geographic exposure across the Americas, EMEA, and Asia-Pacific. The business model relies on an omnichannel network of providers worldwide, leveraging the Hydrafacial brand as a leading professional skincare treatment. The company also offers complementary products such as SkinStylus microneedling and HydraScalp powered by Keravive.

Growth trajectory analysis is limited by the absence of multi-year historical revenue tables in the provided data, but Q1 2026 revenue of $64.9 million represents the latest normalized period performance. The company reported a net loss improvement compared to the prior year period, though specific year-over-year revenue growth rates are not explicitly detailed in the snapshot.

Risk factors include medium dilution risk, as source documents mention dilution or offering risk, and the presence of convertible debt instruments such as the 7.95% Convertible Senior Secured Notes due 2028. The company faces potential listing risk, as the stock price has fallen below the $1.00 minimum bid threshold for 64 consecutive days, triggering a high-severity alert for US continued-listing compliance.

Recent events include the repurchase of 2026 Notes for $20.2 million in Q1 2026, reducing debt obligations. Analyst sentiment is mixed, with a mean recommendation of 3.11 (Hold) and a mean price target of $1.34, suggesting modest upside potential from the current price of $0.94. The company also disclosed partial coverage in Companyfacts, with recent filing facts backfilling cash and equivalents data.

Key takeaways

Strong liquidity position with $523.0 million in cash and zero debt, providing a robust buffer against operational losses.
Negative profitability persists with a -17.2% ROE, driven by high operating expenses relative to gross profit.
Listing risk is elevated due to the stock price remaining below $1.00 for 64 consecutive days, threatening Nasdaq compliance.
Medium dilution risk exists due to outstanding convertible notes and potential equity offerings.
Analyst consensus is neutral (3.11 mean recommendation) with a modest upside target of $1.34.
Revenue model is anchored by high-margin Hydrafacial consumables, supported by a global provider network.

Bull / Bear case

Generated · model-assisted

BULL CASE · 4

Analysts project 70.5% upside to a mean price target of $1.61, significantly above the current market price of $0.94.

The company generated $37.2 million in free cash flow in FY2025, demonstrating strong cash generation despite ongoing net losses.

Capital expenditure intensity is minimal at 0.1% of revenue, well below the 2.4% cohort median, preserving cash for other uses.

Liquidity risk is assessed as low, supported by a current ratio of 1.66, indicating adequate short-term financial stability.

BEAR CASE · 3

The company reported a net loss of $9.5 million in FY2025, continuing a pattern of unprofitability with negative net margins.

Cash conversion is in the bottom quartile of the cohort at -3.94, highlighting poor translation of earnings into cash.

Medium dilution risk exists, potentially eroding shareholder value through future equity issuances to fund operations or growth.

In focus — financials by report

Quarterly

Annual

QUARTERLYFiled 2026-03-31

Q4 2025 · Quarter highlights

Revenue $64.9M; Operating income -$1.8M.

Revenue$64.9M

Operating income-$1.8M

Net income-$6.6M

Free cash flow-$5.8M

EPS—

Operating cash flow-$5.6M

Financials

Income statement

Revenue$64.9M

Gross profit$44.4M

Operating income-$1.8M

Net income-$6.6M

Margins

Gross margin68.5%

Operating margin-2.8%

Net margin-10.2%

FCF margin-8.9%

Balance sheet

Total assets$473.2M

Total liabilities$418.0M

Total equity$55.2M

Cash & equivalents—

Long-term debt—

Cash flow

Operating cash flow-$5.6M

CapEx$224.0k

Free cash flow-$5.8M

SBC$2.1M

P&L flow · revenue → net income

Highlights

▍Revenue $64.9M
▍Operating income -$1.8M
▍Net margin -10.2%

Valuation FY

Market price

$0,62

Market cap

$123.9M

Enterprise valueⓘ

-$399.1M

P/Eⓘ

—

Non-GAAP P/Eⓘ

—

EV / Revenueⓘ

-1.3x

EV / Op incomeⓘ

—

EV / OCFⓘ

-10.7x

P / Bⓘ

—

P / Tangible bookⓘ

—

Tangible book

-$103.8M

Net cashⓘ

$523.0M

Current ratioⓘ

1.8

Debt / equityⓘ

—

ROAⓘ

-2.0%

ROEⓘ

-17.2%

Cash conversionⓘ

-394.0%

CapEx / revenueⓘ

0.1%

SBC / revenueⓘ

4.9%

Dilution ratioⓘ

1.8%

Revenue by segment

Business relationships

Business relationships14 disclosed relationships · 1 type · extracted from filings & disclosures

Subsidiaries14

EX21:176ff5f4ff66EX21:176ff5f4ff66Subsidiarie97%

EX21:33ec8aa77682EX21:33ec8aa77682Subsidiarie97%

EX21:4f04fd7607fcEX21:4f04fd7607fcSubsidiarie97%

EX21:60ef7dded51eEX21:60ef7dded51eSubsidiarie97%

EX21:9bbf5c557fb9EX21:9bbf5c557fb9Subsidiarie97%

EX21:cdd6300b6337EX21:cdd6300b6337Subsidiarie97%

EX21:cf5567dee7a0EX21:cf5567dee7a0Subsidiarie97%

EX21:ddf6742f8fe2EX21:ddf6742f8fe2Subsidiarie97%

EX21:e0ff8ecaf328EX21:e0ff8ecaf328Subsidiarie97%

EX21:e7fb2d17098aEX21:e7fb2d17098aSubsidiarie97%

EX21:ec0bd362d739EX21:ec0bd362d739Subsidiarie97%

EX21:ee603b9ca6f8EX21:ee603b9ca6f8Subsidiarie97%

EX21:f32c24c86c3bEX21:f32c24c86c3bSubsidiarie97%

EX21:fb0b04a1d963EX21:fb0b04a1d963Subsidiarie97%

Supply chain

— missing data

Peer comparison

Peer comparison8 peers · vs SKIN · multiples and returns

PG—

THE PROCTER & GAMBLE COMPANY

$145,25

352,3B USD

P/E

22,1x

— vs self

Div yield

2,8 %

— vs self

ROE

29,2 %

+46,4 vs self

UL—

UNILEVER PLC

—

P/E

—

— vs self

Div yield

—

— vs self

ROE

—

— vs self

CL—

Colgate-palmolive Co

$90,55

72,7B USD

P/E

34,4x

— vs self

Div yield

2,3 %

— vs self

ROE

903,4 %

+920,6 vs self

KMB—

KIMBERLY-CLARK INC.

$107,22

35,6B USD

P/E

60,0x

— vs self

Div yield

5,2 %

— vs self

ROE

47,9 %

+65,1 vs self

KVUE—

KENVUE INC.

$18,04

34,6B USD

P/E

22,7x

— vs self

Div yield

4,3 %

— vs self

ROE

15,1 %

+32,3 vs self

EL—

Estee Lauder Companies

$84,68

30,9B USD

P/E

101,7x

— vs self

Div yield

2,1 %

— vs self

ROE

7,5 %

+24,7 vs self

ELF—

Elf Beauty Inc

$82,75

4,9B USD

P/E

174,5x

— vs self

Div yield

—

— vs self

ROE

2,3 %

+19,6 vs self

MATW—

Matthews Intl Corp

$28,07

873,7M USD

P/E

—

— vs self

Div yield

3,6 %

— vs self

ROE

-5,1 %

+12,1 vs self

Market position

Stress test

— missing data

Predictor forecast

Next quarternear-term

Earnings · next quarterconf 44 %

EPS

Consensus EPS

-0,14

Predicted surprise

+0,08

Beat probability

44 %

Analysts

Other metrics

Revenue

—

no estimate

Segment revenue

—

no estimate

Margin

—

no estimate

Segment margin

—

no estimate

revision ratio -0,01 · as of 2026-07-14 · Earnings Surprise V1

Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.

Full fiscal year~1 year ahead

Full fiscal year · our forecast vs guidance vs consensus

Metric	Our forecast	Guidance	Consensus
EPS	—no estimate	—no estimate	-0,14
Revenue	—no estimate	—no estimate	289,5M USD
Operating income	—no estimate	—no estimate	-1,8M USD

Full-year consensus mean (period as reported by source) · consensus in USD. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.

Corporate eventM&A horizon

M&A probabilityconf 5 %

Probability

5 %

Base rate

3 %

Band

—

180-day horizon · target 2027-01-16 · 1,8× base rate

No acquirer candidates identified by the signal model.

Probabilistic model output — not investment advice. · generated 2026-08-04

Options

— missing data

Short squeeze

— missing data

Earnings-call key lines

— missing data

Consensus distribution

sell-side coverage

Recommendation distribution9 analysts

Strong buy0

Buy1

Hold6

Sell2

Strong sell0

12-month price target$1,34 · Median $1,02

Low $1,00High $2,00

Operating income · consensus-1,8M USD

EPS surprise

+44,8 %

reported vs consensus · beat

Revenue surprise

+3,9 %

reported vs consensus · beat

Estimate revisions

consensus EPS · 26-week trend

— missing data

Sell-side observations

Low$1,00

Mean$1,34

Median$1,02

High$2,00

Spot$0,62

+114.7 %implied to mean12-month sell-side price targets · ▲ spot

Themes

— missing data

ESG

— missing data

Risk factors

Dilution riskMedium

Liquidity riskLow

Filing-based flags

Source documents mention dilution or offering risk.

Benchmarks vs cohort

Op Margin-6,9 %Bottom quartile

Net Margin-3,2 %Bottom quartile

ROE-17,2 %Bottom quartile

Capex / Rev0,1 %Above P75

D/E0,00Above P75

Cash Conv-3,94Bottom quartile

Corporate actions / M&A

M&A probabilityconf —

Probability

5 %

Base rate

3 %

Band

Moderate

180-day horizon · target 2027-01-16 · 1,8× base rate

No acquirer candidates identified by the signal model.

Corporate actionsNo corporate-action source connected yet — splits, dividends and buyback events are not tracked for this company. Honest-dim (no data fabricated).

FX exposure

— missing data

Comparable transactions

— missing data

Derivatives & instruments

— missing data

Actions

Set alert Open in charts

Ask Handelsavisen

— missing data

Data sources

Market data
Regulatory filings
Issuer disclosures
Public news
Earnings transcripts
Consensus estimates
ESG data
Reference data

How metrics are computed

Debt To Equity
(short_term_debt + long_term_debt) / total_equity
Ev To Revenue
enterprise_value / revenue
Market Cap
market_price * shares_outstanding_diluted
Return On Assets
net_income / total_assets
Enterprise Value
market_cap - net_cash
Cash Conversion Ratio
operating_cash_flow / net_income

Source documents

SkinHealth Systems Inc. company facts · 2026-07-12
SkinHealth Systems Inc. 10-Q 2026-05-07 · 2026-07-12
SkinHealth Systems Inc. 10-K 2026-03-12 · 2026-07-12
SkinHealth Systems Inc. 10-Q 2025-11-06 · 2026-07-12
SkinHealth Systems Inc. 10-Q 2025-08-07 · 2026-07-12
ha_price_listing fired on SKIN · 2026-07-12
Skinhealth Systems Inc Market data — analyst estimates · 2026-07-12
Skinhealth Systems Inc Market data — ESG · 2026-07-12
SkinHealth Systems Inc. HA canonical relationships · 2026-07-12

Ownership & reference

Top holders

FMR LLCInstitutional Investor · as of 2026-03-310,00 %$15M
BlackRock Institutional Trust Company, N.A.Investment Managers · as of 2024-06-300,00 %$11M
AQR Capital Management, LLCInvestment Managers · as of 2026-03-310,00 %$0M
Geode Capital Management, L.L.C.Investment Managers · as of 2026-03-310,00 %$2M
Vanguard Capital Management, LLCInvestment Managers · as of 2025-12-310,00 %$8M
Charles Schwab Investment Management, Inc.Investment Managers · as of 2026-03-310,00 %$1M
Northern Trust Investments, Inc.Investment Managers · as of 2026-03-310,00 %$1M
Goldman Sachs Asset Management, L.P.Investment Managers · as of 2026-03-310,00 %$1M
AllianceBernstein L.P.Investment Managers · as of 2026-03-310,00 %$0M
State Street Investment Management (US)Investment Managers · as of 2026-03-310,00 %$2M
Bank of New York Mellon CorpInstitutional Investor · as of 2026-03-310,00 %$0M
UBS Financial Services, Inc.Investment Managers · as of 2026-03-310,00 %$0M
Nuveen LLCInvestment Managers · as of 2024-12-310,00 %$0M
Dimensional Fund Advisors, L.P.Investment Managers · as of 2026-03-310,00 %$0M
T. Rowe Price Associates, Inc.Investment Managers · as of 2026-03-310,00 %$0M
Invesco QQQ TrustFunds · as of 2026-03-310,00 %$0M
Franklin Advisers, Inc.Investment Managers · as of 2026-03-310,00 %$0M
Wells Fargo AdvisorsBrokerage Firms · as of 2026-03-310,00 %$0M
Morgan Stanley Smith Barney LLCInvestment Managers · as of 2026-03-310,00 %$0M
Raymond James & Associates, Inc.Brokerage Firms · as of 2026-03-310,00 %$0M
JONES FINANCIAL COMPANIES LLLPInstitutional Investor · as of 2026-03-310,00 %$0M
PNC Investments LLCInvestment Managers · as of 2026-03-310,00 %$0M

Leadership

Marla Malcolm BeckPresident, Chief Executive Officer, Director

Insider activity

Mixed / flat0 buys · 0 sellsnet $05 insiders · last 365d

Lewis SheriCSO and COO · Class A Common StockOther 24 904 @ $0,92$23K · 2026-04-09
MONAHAN MICHAEL P.Chief Financial Officer · Class A Common StockOther 26 776 @ $0,92$25K · 2026-04-09
Malha Pedro Bruno FerreiraDirector, President and CEO · Class A Common StockOther 2 654 867 · 2026-03-20
MONAHAN MICHAEL P.Chief Financial Officer · Class A Common StockOther 746 681 · 2026-03-20
Menezes RonaldChief Revenue Officer · Class A Common StockOther 746 681 · 2026-03-20
Lewis SheriCSO and COO · Class A Common StockOther 746 681 · 2026-03-20
Lewis SheriCSO and COO · Class A Common StockOther 51 883 @ $1,17$61K · 2026-03-17
Menezes RonaldChief Revenue Officer · Class A Common StockOther 61 471 @ $1,17$72K · 2026-03-17
MONAHAN MICHAEL P.Chief Financial Officer · Class A Common StockOther 58 573 @ $1,17$69K · 2026-03-17
SCHAISON PHILIPPEDirector · Class A Common StockOther 57 692 · 2025-11-13
Menezes RonaldChief Revenue Officer · Class A Common StockOther 46 426 @ $1,43$66K · 2025-11-01
Malha Pedro Bruno FerreiraDirector, President and CEO · Class A Common StockOther 1 228 846 @ $1,56$1,9M · 2025-10-09
Malha Pedro Bruno FerreiraDirector, President and CEO · Class A Common StockOther 961 538 @ $1,56$1,5M · 2025-10-09
MONAHAN MICHAEL P.Chief Financial Officer · Class A Common StockOther 32 357 @ $1,89$61K · 2025-08-10

Short positioning

8.8Mshares short-10.2% vs prior

1days to cover

39.7%short of daily vol

10.2Kfails-to-deliver

as of 2026-07-15 · short-interest report (free)

Geographic breakdown

— missing data

Listings · one canonical issuer all listings resolve to the canonical

SKINCanonical

Nasdaq · USD

Intel & risk

PredictorBeat prob44 %Surprise+0,08M&A prob5 %Full forecast →

What changed

no material change vs prior analysis (walked 17 fields; 4 schema-expansion field(s) excluded)

Narrative— → —medium
Conclusion— → —medium
Key takeaways— → —medium
Company share pct— → —medium

vs prior analysis today

peak dispatch · 2026-07-16

OSINT findings

Dilution riskMedium

Liquidity riskLow

Source documents mention dilution or offering risk.

Relationship graph

This companySectorSubsidiaries

Evidence & claims

From filings & derived data

Cost of revenue (YoY) (2025-12-31 vs 2024-12-31): -31.3%Derived (calculated)
EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): 55.6%Derived (calculated)
Operating income (YoY) (2025-12-31 vs 2024-12-31): 69.3%Derived (calculated)
Total liabilities (YoY) (2025-12-31 vs 2024-12-31): -30.8%Derived (calculated)
Total assets (YoY) (2025-12-31 vs 2024-12-31): -27.1%Derived (calculated)
Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): 17.9%Derived (calculated)
Revenue (YoY) (2025-12-31 vs 2024-12-31): -10.0%Derived (calculated)
Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): 132.3%Derived (calculated)
Net income (YoY) (2025-12-31 vs 2024-12-31): 67.4%Derived (calculated)
Net margin (FY 2025-12-31): -3.2%Derived (calculated)
Gross margin (FY 2025-12-31): 65.3%Derived (calculated)
Return on equity (FY 2025-12-31): -15.6%Derived (calculated)
Return on assets (FY 2025-12-31): -1.9%Derived (calculated)
Current ratio (FY 2025-12-31): 1.66xDerived (calculated)
Debt-to-equity (FY 2025-12-31): 7.19xDerived (calculated)
R&D expense (YoY) (2025-12-31 vs 2024-12-31): -10.6%Derived (calculated)
Capex (YoY) (2025-12-31 vs 2024-12-31): -59.9%Derived (calculated)
Gross profit (YoY) (2025-12-31 vs 2024-12-31): 7.7%Derived (calculated)
EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): 65.2%Derived (calculated)
Total liabilities (annual): USD 438.75MSEC XBRL filing
Cost of revenue (annual): USD 104.43MSEC XBRL filing
Revenue (annual): USD 300.79MSEC XBRL filing
Pre-tax income (annual): USD -5.94MSEC XBRL filing
EPS (basic) (annual): USD-PER-SHARES -0SEC XBRL filing

Showing 24 of 60 surfaced claims.

Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.

The Thread

Everything we know, in order

2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date

2026-07-16 12:49 UTCNEWSSkinHealth Systems thesis revised as price action triggers monitor alert →

2026-07-16 12:49 UTCNEWSHandelsavisen revises Skinhealth Systems thesis after sector classification audit → Internal data correction triggers fresh analysis for the dermatology firm, resetting valuation benchmarks for investors tracking the stock.

2026-07-11 21:54 UTCEVENTHa Price Move SKIN extraordinary up move (41.754% 1d, 3.96x sigma) on x71.821 volume

2026-07-09 21:54 UTCEVENTHa Price Listing SKIN price below 1 ($0.943) — US continued-listing minimum-bid threshold

2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)

2026-06-30 03:38 UTCEARNINGSUpcomingForecast: ma_probability (180d)

2026-06-21 02:57 UTCHOLDERInstitutional holding changed

2026-06-21 02:57 UTCHOLDER3 institutional position changes flagged

2026-06-16FILING8-K filing →

2026-05-12FILING8-K filing →

2026-05-07FILING10-Q filing →

2026-05-07FILING8-K filing →

2026-05-06FILING8-K filing →

2026-04-24FILINGDEFINITIVE PROXY STATEMENT →

2026-04-22FILING8-K filing →

2026-04-09 00:00 UTCINSIDER2 insider transactions — 2026-04

2026-04-09INSIDERLewis Sheri transacted 24.9k sh Class A Common Stock — CSO and COO ~$23k

2026-04-09INSIDERMONAHAN MICHAEL P. transacted 26.8k sh Class A Common Stock — Chief Financial Officer ~$25k

2026-03-31EARNINGSQuarterly results — Q4 2025 Revenue USD 64.9M · Net USD -6.6M

2026-03-20 00:00 UTCINSIDER7 insider transactions — 2026-03 · net sell $201k

2026-03-20INSIDERMalha Pedro Bruno Ferreira transacted 2.65M sh Class A Common Stock — Director, President and CEO

2026-03-20INSIDERMONAHAN MICHAEL P. transacted 746.7k sh Class A Common Stock — Chief Financial Officer

2026-03-20INSIDERMenezes Ronald transacted 746.7k sh Class A Common Stock — Chief Revenue Officer

2026-03-20INSIDERLewis Sheri transacted 746.7k sh Class A Common Stock — CSO and COO

2026-03-17INSIDERLewis Sheri transacted 51.9k sh Class A Common Stock — CSO and COO ~$61k

2026-03-17INSIDERMenezes Ronald transacted 61.5k sh Class A Common Stock — Chief Revenue Officer ~$72k

2026-03-17INSIDERMONAHAN MICHAEL P. transacted 58.6k sh Class A Common Stock — Chief Financial Officer ~$69k

2026-03-12FILING10-K filing →

2026-03-12FILING8-K filing →

2026-03-06FILING8-K filing →

2025-12-31EARNINGSQuarterly results — Q3 2025

2025-12-31EARNINGSAnnual results — FY 2025 Revenue USD 300.8M · Net USD -9.5M

2025-11-13 00:00 UTCINSIDER2 insider transactions — 2025-11

2025-11-13INSIDERSCHAISON PHILIPPE transacted 57.7k sh Class A Common Stock — Director

Showing the 40 most recent of 52 entries.

The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.

Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data · Reference data Premium coverage

Analyst recommendations

At a glance

What drives this business

News & coverage

Sector rotation

Developing storylines

Analysis

Opportunity

Upcoming catalysts

Pre-earnings brief

Signals & dispatch

Composite-score breakdown

Synthesis

Bull / Bear case

In focus — financials by report

Valuation FY

Revenue by segment

Market share

Business relationships

Supply chain

Peer comparison

Market position

Stress test

Predictor forecast

Options

Short squeeze

Earnings-call key lines

Consensus distribution

Estimate revisions

Sell-side observations

Themes

ESG

Risk factors

Benchmarks vs cohort

Corporate actions / M&A

FX exposure

Comparable transactions

Derivatives & instruments

Actions

Ask Handelsavisen

Ownership & reference

Top holders

Leadership

Insider activity

Short positioning

Geographic breakdown

Intel & risk

Evidence & claims

The Thread